Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of October 2015

Commission file number 0-30752

AETERNA ZENTARIS INC.

1405 du Parc-Technologique Boulevard

Quebec City, Québec

Canada, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

DOCUMENTS INDEX

Documents		Description
99.1		Press Release dated October 12, 2015
99.2		Material Change Report of the Registrant dated October 13, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.


By:	/s/ Philip A. Theodore
	Philip A. Theodore
	Senior Vice President
Date: October 13, 2015

Exhibit 99.1

Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations
and Closure of Quebec City Office

Quebec City, Canada, October 12, 2015 — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today announced the departure of Dennis Turpin, the Company’s former Senior Vice President, Chief Financial Officer, and the decision to close its Quebec City office.

David A. Dodd, Chairman, President and Chief Executive Officer of the Company commented, “After a comprehensive review, the Company’s Board reached the decision to take these actions, including the closure of our Quebec City office by the end of December, making all associates based there redundant. We will transfer many of the functions now performed in our Quebec City office to other personnel and we will strengthen our financial team with the addition of new finance and accounting personnel in our Charleston, South Carolina office. A comprehensive search for a Chief Financial Officer and the other finance and accounting personnel required is underway. Mr. Keith Santorelli, our Vice President, Finance, will succeed Mr. Turpin as our Chief Accounting Officer, with responsibility for all internal and external financial reporting on an interim basis while the Company conducts an external search for a permanent CFO. We appreciate Keith’s leadership and commitment to ensuring a smooth transition in our finance and accounting function.”

“I would like to thank our colleagues in Quebec City for their contributions to the Company. This decision was difficult but necessary. With these actions, we intend to create value for our shareholders by

· Enhancing shareholder and investment community confidence and support

· Improving our operating effectiveness and efficiency and

· Increasing the strength of our management team.

We will provide information regarding the financial implications of these actions during our discussion of our third quarter results.”

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. For more information, visit www.aezsinc.com.

Contact

Philip A. Theodore
Senior Vice President
843-900-3211
ptheodore@aezsinc.com

-30-

Exhibit 99.2

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Aeterna Zentaris Inc.
1405 du Parc-Technologique Boulevard
Quebec City, Quebec
Canada, G1P4P5

Item 2 Date of Material Change

October 9, 2015

Item 3 News Release

On October 12, 2015, the Company issued a news release indicating the material change, which was disseminated in Canada on the CNW newswire service.

Item 4 Summary of Material Change

On October 9, 2015, the Company’s Board of Directors determined to terminate immediately the employment of Mr. Dennis Turpin, the Company’s former Senior Vice President, Chief Financial Officer, and to close the Company’s office in Quebec City, Quebec by December 31, 2015, making all associates based there redundant. These decisions were communicated to Mr. Turpin and the other affected employees of the Company on October 9, 2015. A comprehensive search for a Chief Financial Officer is underway. Mr. Keith Santorelli, the Company’s Vice President, Finance, will succeed Mr. Turpin as the Company’s Chief Accounting Officer, with responsibility for all internal and external financial reporting on an interim basis while the Company conducts an external search for a permanent Chief Financial Officer.

Item 5 Full Description of Material Change

See Item 4.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

Not applicable

Item 8 Executive Officer

Further information regarding the matters described in this report may be obtained from Philip A. Theodore, Senior Vice President, General Counsel. Mr. Theodore is knowledgeable about the details of the material change and may be contacted at (843) 900-3211.

Item 9 Date of Report

October 13, 2015

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024